Skip to search formSkip to main contentSkip to account menu

SM 1652

Known as: SM-1652 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

cefpiramide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1988
1988
Renal tubular mechanisms for excretion of cefpiramide (SM-1652) in association with its long-lasting pharmacokinetic properties.
To investigate possible mechanisms for the long-lasting pharmacokinetic properties of cefpiramide, pharmacokinetic and renal… 
1986
1986
In vitro activity of cefpiramide (SM-1652) against gram-negative bacilli.
1984
1984
Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics
We evaluated the in vitro synergistic activity at clinically attainable concentrations of combinations of aminoglycoside and beta… 
1983
1983
Metabolic fate of [14C]SM-1652, a new antipseudomonal cephalosporin, after parenteral administration to rats
A study of the metabolic fate of [14C]SM-1652 after intravenous or intramuscular injection into rats showed that: (i) the… 
1983
1983
Cefpiramide (SM-1652) の健常成人における体内動態
1983
1983
慢性複雑性尿路感染症に対するCeftazidime (SN401) の使用経験
1983
1983
Cefpiramide (SM-1652) の口腔組織移行に関する実験的・臨床的検討
1983
1983
呼吸器感染症におけるCeftazidime (SN401) の臨床的検討
1983
1983
口腔外科領域の各種感染症に対するCefpiramide (SM-1652) の臨床成績
1983
1983
[Double-blind comparative clinical study of cefpiramide (SM-1652) and cefsulodin on complicated urinary tract infections due to P. aeruginosa].
The therapeutic efficacy and safety of Cefpiramide (CPM, SM-1652) at a 2 g/day dose were objectively compared with those of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)